Science 37 Holdings, Inc. (Nasdaq: SNCE), the clinical research
industry-leading Metasite™, has been named the winner of the
prestigious "Best Overall Clinical Trial Platform" award in the 7th
annual MedTech Breakthrough Awards program. Science 37 was chosen
by MedTech Breakthrough, an autonomous market intelligence
organization that recognizes the top companies, technologies, and
products in the global health and medical technology market, in
recognition of the Metasite and its transformation of clinical
research.
Built on a proprietary unified platform, the Science 37
Metasite, transforms clinical research by enabling patients to
participate in trials from the comfort of their homes. The Science
37 unified platform delivers trial orchestration and data capture
in a single, end-to-end platform that guides the workflow for
patients and study staff, and electronically captures study data.
The platform enables eConsent, ePRO, telemedicine, scheduling, and
wearable/ device integration to deliver clinical trials directly to
patients, wherever they are. The result is consistent user
journeys, greater compliance, and high-quality data.
“Virtual clinical trials are transforming research by putting
patient needs first,” said Troy Bryenton, Chief Technology Officer
of Science 37. “The Metasite improves the participant experience by
delivering accessible and flexible research options and provides
data from a more diverse and real-world sample. Our unified
platform makes this possible by delivering the infrastructure that
orchestrates the user journey and enables data collection from
anywhere.”
The mission of the MedTech Breakthrough Awards is to honor
excellence and recognize innovation, hard work, and success in a
range of health and medical technology categories, including
Telehealth, Clinical Administration, Patient Engagement, Electronic
Health Records (EHR), Virtual Care, Medical Devices, Medical Data,
and more. This year’s program attracted more than 4,000 nominations
from over 17 different countries throughout the world.
James Johnson, managing director of MedTech Breakthrough, said,
“Science 37 is helping to transform clinical research by meeting
patients wherever they are, through a decentralized clinical trial
model. By offering a complete virtual site solution, Science 37
helps eliminate geographic restrictions, providing convenience with
a patient-focused, end-to-end clinical trial experience.
Congratulations on being the ‘Best Overall Clinical Trial
Platform’.”
Science 37’s unified platform allows for easy-to-follow and
standardized processes that deliver greater consistency,
compliance, and data accuracy, ensuring reliability for regulators
according to GCP standards. From enrollment through to study
completion, the patient follows intuitive, app-based processes
using their everyday mobile devices or provisioned devices. All
data is captured directly into the Science 37 unified platform from
all trial stakeholders, including the mobile nurse, who records
procedure results as they are performed at the participant’s home.
Every step of the patient journey with the Metasite is a high-touch
experience that drives study conduct excellence.
About Science 37Science 37 Holdings, Inc.’s (Nasdaq: SNCE)
mission is to accelerate clinical research by enabling universal
trial access for patients. Through our Metasite™ we reach an
expanded population beyond the traditional site, delivering on our
goal of clinical research that works for everyone—with greater
patient diversity. Patients gain the flexibility to participate
from the comfort of their own homes, at their local community
provider, or at a traditional site when needed. Our Metasite is
powered by a proprietary technology platform with in-house medical
and operational experts that drive uniform study orchestration,
enabling greater compliance and high-quality data. To learn more,
visit www.science37.com, or email science37@science37.com.
About MedTech Breakthrough
Part of Tech Breakthrough, a leading market intelligence and
recognition platform for global technology innovation and
leadership, the MedTech Breakthrough Awards program is devoted to
honoring excellence and innovation in medical & health
technology companies, products, services and people. The MedTech
Breakthrough Awards provide a platform for public recognition
around the achievements of breakthrough healthcare and medical
companies and products in categories that include Patient
Experience & Engagement, Health & Fitness, Medical Devices,
Clinical Administration, Connected Healthcare, Medical Data,
Healthcare Cybersecurity and more. For more information visit
MedTechBreakthrough.com.
Cautionary Note Regarding Forward-Looking
Statements
This press release contains certain forward-looking statements
within the meaning of the federal securities laws, including
statements regarding the products offered by Science 37 and the
markets in which it operates, and Science 37’s anticipated growth
and profitability. These forward-looking statements generally are
identified by the words “believe,” “can,” “could”, “seek”,
“project,” “expect,” “anticipate,” “estimate,” “intend,”
“strategy,” “future,” “opportunity,” “plan,” “may,” “might”,
“should,” “will,” “would,” “will be,” “will continue,” “will likely
result” and similar expressions. Forward-looking statements are
predictions, projections and other statements about future events
that are based on current expectations and assumptions and, as a
result, are subject to risks and uncertainties. Many factors could
cause actual future events to differ materially from the
forward-looking statements in this press release, including but not
limited to: (i) the ability to maintain the listing of Science 37’s
securities on The Nasdaq Stock Market LLC, (ii) volatility in the
price of Science 37’s securities due to a variety of factors,
including changes in the competitive and highly regulated
industries in which Science 37 operates, variations in performance
across competitors, changes in laws and regulations affecting
Science 37’s business, changes in its capital structure, and
general economic and financial market conditions, including
fluctuations in currency exchange rates, economic instability, and
inflationary conditions (iii) the ability to implement business
plans, forecasts, and other expectations, and to identify and
realize additional opportunities, (iv) the risk that Science 37 may
never achieve or sustain profitability, (v) the risk that Science
37 will need to raise additional capital to execute its business
plan, which may not be available on acceptable terms or at all,
(vi) failure to realize anticipated cost savings, and (vii) risks
related to general economic and financial market conditions. The
foregoing list of factors is not exhaustive. You should carefully
consider the foregoing factors and the other risks and
uncertainties described in the “Risk Factors” section of Science
37’s Annual Report on Form 10-K for the fiscal year ended December
31, 2022 filed with the U.S. Securities and Exchange Commission
(the “SEC”) on March 6, 2023 and in the other documents filed by
Science 37 from time to time with the SEC. These filings identify
and address other important risks and uncertainties that could
cause actual events and results to differ materially from those
contained in the forward-looking statements. Forward-looking
statements speak only as of the date they are made. Readers are
cautioned not to put undue reliance on forward-looking statements,
and Science 37 assumes no obligation and does not intend to update
or revise these forward-looking statements, whether as a result of
new information, future events, or otherwise, except as required by
law. Science 37 does not give any assurance that Science 37 will
achieve its expectations.
MEDIA INQUIRIES:Grazia MohrenScience 37PR@science37.com
INVESTOR RELATIONS:Steve HalperLifeSci
AdvisorsInvestors@science37.com
Science 37 (NASDAQ:SNCE)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Science 37 (NASDAQ:SNCE)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024